Wang Tao, Khan Aawrish, Gong Lunli, Hong Kim, Qi Lili, Cui Haiyan
Department of Plastic and Cosmetic Surgery, Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200092, People's Republic of China.
Institute of Aesthetic Plastic Surgery and Medicine, School of Medicine, Tongji University, Shanghai, 200092, People's Republic of China.
Aesthetic Plast Surg. 2025 May;49(9):2399-2410. doi: 10.1007/s00266-025-04764-5. Epub 2025 Mar 10.
Collagen is currently a widely used injectable filler material. Due to the complexity and specificity of the infraorbital structure and function, it undergoes various aging changes earlier in the facial aging process. Additionally, continuous exposure to Ultraviolet (UV) leads to photoaging of the skin. In this study, we utilized type I and type III composite collagen as a filler material for injecting the infraorbital region of the human face and the dorsal region of a nude mouse skin photoaging model to assess its effectiveness and safety.
To assess the effectiveness of type I and type III composite collagen in treating age-related changes in the human infraorbital area, as well as in a nude mouse model of skin aging.
A total of 36 patients with infraorbital aging were enrolled to receive type I and type III composite collagen injections. The improvement of infraorbital aging was assessed at pre-injection, immediate post-injection, 1 week, 4 weeks, and 12 weeks. Additionally, nude mice photodamaged models were prepared and collagen injections were administered to treat photodamaged skin. The therapeutic efficacy was assessed by gross view, histological staining, gene expression analysis, and ELISA assay.
Type I and Type III composite collagen injection can immediately fill depressed areas. However, one week after the injection, the collagen dehydrates and contracts, causing the material to be absorbed by the tissues and resulting in a slight regression of the filling effect. After one month, some of the collagen has degraded, with most of it degrading after three months. Additionally, in treating photoaging, type I and type III composite collagen has a more pronounced therapeutic effect on photoaging and demonstrates better results in collagen regeneration, inflammation reduction, and melanin control.
Type I and Type III composite collagen demonstrates superior efficacy and safety in addressing infraorbital aging and photoaging in nude mice skin, making it a more favorable choice as an injection material.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
胶原蛋白是目前广泛应用的可注射填充材料。由于眶下结构和功能的复杂性及特殊性，其在面部衰老过程中较早出现各种老化改变。此外，持续暴露于紫外线会导致皮肤光老化。在本研究中，我们使用I型和III型复合胶原蛋白作为填充材料，注射到人脸眶下区域及裸鼠皮肤光老化模型的背部区域，以评估其有效性和安全性。
评估I型和III型复合胶原蛋白治疗人类眶下区域与年龄相关变化以及裸鼠皮肤老化模型的有效性。
共纳入36例眶下老化患者接受I型和III型复合胶原蛋白注射。在注射前、注射后即刻、1周、4周和12周评估眶下老化的改善情况。此外，制备裸鼠光损伤模型并注射胶原蛋白以治疗光损伤皮肤。通过大体观察、组织学染色、基因表达分析和酶联免疫吸附测定评估治疗效果。
I型和III型复合胶原蛋白注射可立即填充凹陷区域。然而，注射1周后，胶原蛋白脱水收缩，导致材料被组织吸收，填充效果略有消退。1个月后，部分胶原蛋白降解，3个月后大部分胶原蛋白降解。此外，在治疗光老化方面，I型和III型复合胶原蛋白对光老化具有更显著的治疗效果，在胶原蛋白再生、减轻炎症和控制黑色素方面表现出更好的效果。
I型和III型复合胶原蛋白在解决裸鼠皮肤眶下老化和光老化方面显示出卓越的疗效和安全性，使其成为更理想的注射材料选择。
证据水平II：本刊要求作者为每篇文章指定证据水平。有关这些循证医学评级的完整描述，请参阅目录或作者在线指南www.springer.com/00266 。
